What is it about?
Achromobacter xylosoxidans is a bacterium found in the environment that increasingly causes infections in vulnerable people, especially those with cystic fibrosis, lung transplant recipients and immunocompromised patients. It is naturally resistant to many antibiotics because it pumps drugs out of the cell, produces enzymes that destroy them and has a poorly permeable outer membrane, so treatment options are limited. Cefiderocol is a recent antibiotic that enters bacteria using their own iron-uptake systems, like a 'Trojan horse'. We reviewed all published laboratory and clinical data on cefiderocol against Achromobacter. Overall, studies show good activity of cefiderocol against this bacterium, and encouraging clinical experiences, although susceptibility varies between isolates and studies.
Featured Image
Photo by Julia Koblitz on Unsplash
Why is it important?
Achromobacter infections are difficult to treat and often affect patients with few remaining options. This is the first focused synthesis of the evidence on cefiderocol for this pathogen, helping clinicians decide when it can be considered and underlining the importance of susceptibility testing for each isolate. It also identifies gaps, such as standardized testing methods and larger clinical studies.
Perspectives
Rare, multidrug-resistant pathogens like Achromobacter are often overlooked, yet for patients with cystic fibrosis or a lung transplant they can be a serious problem. Reviews like this help translate scattered case reports into practical guidance. It was a pleasure to work again with Nicholas Geremia and a network of young Italian infectious diseases specialists.
Professor Stefano Di Bella
Universita degli Studi di Trieste
Read the Original
This page is a summary of: In vitro
activity and clinical use of cefiderocol against
Achromobacter xylosoxidans
(Review), Biomedical Reports, August 2026, Spandidos Publications,
DOI: 10.3892/br.2026.2185.
You can read the full text:
Contributors
The following have contributed to this page







